This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Acromegaly is a chronic disease of adulthood resulting from excessive secretion of growth hormone (GH) and the subsequent elevation of insulin-like growth factor-I (IGF-I).1 It is usually caused by a benign tumour in the anterior pituitary gland.2
Acromegaly is equally prevalent in men and women, with a worldwide estimate of 50-70 cases per million,1,3 although more recent studies have estimated this number to be higher,4 and an annual incidence of 3-4 cases per million.3
The mean age of diagnosis is approximately 40 years,1 and diagnosis takes an average of 7-10 years from onset of symptoms.5 If left untreated or unsuccessfully treated, acromegaly is associated with increased mortality and risk of metabolic and cardiovascular complications;1,3 the mortality rate for patients with uncontrolled acromegaly is approximately 2–3 times higher than that of the general population.6
Acromegaly affects virtually all organs and tissues, causing metabolic, cardiovascular, neurological and musculoskeletal morbidities.6 The clinical signs can result from chronic exposure to the effects of GH and IGF-I and/or a secondary effect of the mass of the tumour.3
To find out more about homecare, supporting patients or ordering more starter kits
Learn more about Somavert reimbursement in your area and how to arrange funding
Discover IGF-I normalisation rates with Somavert
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024